

September 18, 2024

Press Release

European Federation of Pharmaceutical Industries and Associations (EFPIA Japan)

EFPIA Japan Announces Winners for 7th “PASE AWARD” Patient Organization Support Program

TOKYO – 18th September 2024 - The European Federation of Pharmaceutical Industries and Associations (EFPIA Japan, Chair: Takahiko Iwaya) announced the following award winners for the 7th PASE AWARD, a Patient Advocacy Support program by EFPIA Japan.

PASE AWARD is a patient organization support program established in 2017 with the goal of encouraging patient group activities in Japan and developing a better healthcare environment surrounding patients by reflecting patients’ voices appropriately in the healthcare system.

7th PASE AWARD Winners

Name of organization	Awarded Implementation Plan	Grant JPY
Certified Non-Profit Organization KIBOUNOKAI	International Collaboration for SDM Promotion and QOL Improvement	500,000
Systemic Scleroderma Patient Group Linkage	Solving problems of medical consultation with this one book! - Guidebook for Scleroderma Consultation for SDM	220,000
Rheumatic Disease & Vasculitis Support Network JAPAN	To help children with pediatric collagen disease live every day with peace of mind - Project to deliver picture books to schools	500,000
Pancreatic Cancer Action Network Japan (PanCAN Japan)	Adult-onset diabetes and pancreatic cancer early detection awareness program Medical seminar “Pancreatic Cancer and Adult-Onset Diabetes”	500,000
PPeCC, Inc.	Development of “Itadakimasu Together Project” campaign to raise awareness by visualizing the dietary needs of patients	500,000

The theme for this year's PASE AWARD entries was “improving the health and quality of life of patients”. A total of 15 entries were received by July 5. Through the selection process consisting of a primary document review and a final review with a presentation and Q&A, five organizations received the PASE AWARD this year.

Last year, the eligibility was expanded to unincorporated patient organizations and patient support organizations. This year's award will provide grants covering up to 50% of an organization's annual budget of revenues and expenses, with a maximum of 500,000 yen and a minimum of 150,000 yen depending on the size of the organization.

The selection committee members for the final review are as follows:

Prof. Takeo Nakayama (Kyoto University Faculty of Medicine, Professor of Health Informatics)
Prof. Tomoko Takayama (Shizuoka Graduate University of Public Health, Professor of Public Health)
Dr. Sho Inoue (Medical Note, Inc., Co-founder & Representative)
Mr. Takahiko Iwaya, EFPIA Japan Chair (Sanofi K.K.)
Mr. Takafumi Horii, EFPIA Japan Vice Chair (AstraZeneca K.K.)
Mr. Kasper Bødker Mejlvang, EFPIA Japan Vice Chair (Novo Nordisk Pharma Ltd.)
Dr. Jan Stefan Scheld, EFPIA Japan Board Director (Nippon Boehringer Ingelheim Co., Ltd.)
Mr. Daisuke Uchida, EFPIA Japan Governance and Legal Committee Chair (Sanofi K.K.)

Takahiko Iwaya, Chair of EFPIA Japan, commented, “I would like to thank all the patient organizations that applied for the 7th PASE AWARD. As the healthcare landscape surrounding patients changes, patient organizations play a broad range of key roles. EFPIA Japan will continue to support, collaborate with, and build stronger relationships with patient organizations that contribute to the development of the healthcare environment, thus enabling ‘patient-centric healthcare.’”

Winners with the highest recognition will present their activity plans at the award ceremony to be held on October 9.

About the EFPIA Japan Patient Association Program “PASE AWARD”

EFPIA Japan works with patients to support opportunities and activities that address patient needs and policy proposals. The PASE (Patient Advocacy Support by EFPIA Japan) AWARD was established in 2017 to encourage patient group activities in Japan. Over the past 7 years, a total of 121 organizations applied for the AWARD with a wide range of activity plans. This year, EFPIA Japan will provide a total of 2,220,000 yen in grants to 5 organizations.

See the link for more information about PASE.

<http://efpia.jp/pase/index.html>

About EFPIA Japan (European Federation of Pharmaceutical Industries and Associations Japan) (<http://efpia.jp/>)<http://efpia.jp/>

Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceutical companies operating in Japan. In 2023, combined sales from the member companies accounted for roughly 28% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations) (<http://www.efpia.eu>)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 37 national associations, 40 leading pharmaceutical companies and a growing number of small and medium-sized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.



European Federation of Pharmaceutical
Industries and Associations

Contact:

Hitoshi Fujita
EFPIA Japan, Communications Working Team
〒105-6333
1-23-1 Toranomom 1, Minato-ku, Tokyo
Toranomom Hills Mori Tower
Novartis Pharma K.K.
TEL: 090-9837-4326
Mail: hitoshi.fujita@novartis.com

Mayumi Kaneda (Person in charge of PASE)
EFPIA Japan Patient Committee
〒153-8926
1-8-1, Shimomeguro, Meguro-ku, Tokyo
4th floor, Alco Tower
Merck Biopharma Co., Ltd.
TEL: 070-8821-5436
Mail: mayumi.kaneda@merckgroup.com